Fig. 2

Immunoblotting of treated cell lines. Western blot of depicting p-ROS1 (Tyr 2274), the different ROS1 isoforms expressed by HCC78 cells (total ROS1), p-Erk 1/2 (Thr 202 / Tyr 204), total Erk 1/2 and GAPDH of ceritinib (a) IC50s: WT = 1.5 nM, G2032R = 179.3, L2026M = 44.18, S1986Y = 101.6; repotrectinib (b) IC50s: WT = 14 nM, G2032R = 318 nM, L2026M = 165.3 nM, S1986Y = 56.4 nM, lorlatinib (c) IC50s: WT = 1.13 nM, G2032R = 59.52 nM, L2026M = 2 nM, S1986Y = 1.81 nM; entrectinib (d) IC50s: WT = 13.52 nM, G2032R = 207 nM, L2026M = 18.5 nM, S1986Y = 15.5 nM and crizotinib (e) IC50s: WT = 112 nM, G2032R = 1692 nM, L2026M = 601 nM and S1986Y = 214.4 nM. f Bar plot reflecting the fold change of normalized p-ROS1 (Tyr 2274) levels relative to ROS1 wild type across TKI treatments in 2D culture